American Psychiatric Association (2000) Practice guideline for the treatment of patients with major depressive disorder (revision). American Journal of Psychiatry, 157 (suppl. 4), 1–45.
Anderson, I. M., Nutt, D. J. & Deakin, J. F. W. (2000) Evidence-based guidelines for treating depressive disorders with antidepressants, a revision of the 1993 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology, 14, 3–20.
Aronson, R., Offman, H. J., Joffe, R. T.
et al (1996) Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Archives of General Psychiatry, 53, 842–848.
Austin, M.-P. V., Souza, F. G. M. & Goodwin, G. M. (1991) Lithium augmentation in antidepressant-resistant patients, a quantitative analysis. British Journal of Psychiatry, 159, 510–514.
Barrett, J. E., Williams, J. W. J., Oxman, T. E.
et al (2001) Treatment of dysthymia and minor depression in primary care, a randomized trial in patients aged 18 to 59 years. Journal of Family Practice, 50, 405–412.
Bauer, M. & Dopfmer, S. (1999) Lithium augmentation in treatment-resistant depression, meta-analysis of placebo-controlled studies. Journal of Clinical Psychopharmacology, 19, 427–434.
Bauer, M., Whybrow, P. C., Angst, J.
et al (2002) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 1. Acute and continuation treatment of major depressive disorder. World Journal of Biological Psychiatry, 3, 5–43.
Canadian Psychiatric Association, the Canadian Network for Mood and Anxiety Treatments (CANMAT) (2001) Clinical guidelines for the treatment of depressive disorders. Canadian Journal of Psychiatry, 46 (suppl. 1), 1S–91S.
Carney, S., Geddes, J., Davies, C.
et al (2001) Duration of treatment with antidepressants (Cochrane Review). Journal of Psychopharmacology, 15 (suppl. 3), A10.
Dornseif, B. E., Dunlop, S. R., Potvin, J. H.
et al (1989) Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacology Bulletin, 25, 71–79.
Ferreri, M., Lavergne, F., Berlin, I.
et al (2001) Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatrica Scandinavica, 103, 66–72.
Khan, A., Leventhal, R. M., Khan, R. K.
et al (2002) Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. Journal of Clinical Psychopharmacology, 22, 40–45.
Lenox-Smith, A. J., Schaeffer, P., Reynolds, A.
et al (2001) A double-blind trial of venlafaxine XR vs citalopram in patients with severe depression. Journal of Psychopharmacology, 15 (suppl. 3), A11.
Licht, R. W. & Qvitzau, S. (2002) Treatment strategies in patients with major depression not responding to first-line sertraline treatment: a randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology, 161, 143–151.
Lima, M. S. & Moncrieff, J. (2002) Drugs versus placebo for dysthymia. Cochrane Library, issue 1. Oxford: Update Software.
McAskill, R., Mir, S. & Taylor, D. (1998) Pindolol augmentation of antidepressant therapy. British Journal of Psychiatry, 173, 203–208.
Mendels, J., Johnston, R., Mattes, J.
et al (1993) Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacology Bulletin, 29, 169–174.
Moncrieff, J. (2002) The antidepressant debate. British Journal of Psychiatry, 180, 193–194.
Montgomery, S. A. (1995) Selecting the optimum therapeutic dose of serotonin reuptake inhibitors, studies with citalopram. International Clinical Psychopharmacology, 10 (suppl. 1), 23–27.
Montgomery, S. A., Rasmussen, J. G. & Tanghoj, P. (1993) A 24–week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. International Clinical Psychopharmacology, 8, 181–188.
Ottevanger, E. A. (1991) The efficacy of fluvoxamine in patients with severe depression. British Journal of Clinical Research, 2, 125–132.
Paykel, E. S., Freeling, P. & Hollyman, J. A. (1988) Are tricyclic antidepressants useful for mild depression? A placebo controlled trial. Pharmacopsychiatry, 21, 15–18.
Peveler, R., George, C., Kinmonth, A. L.
et al (1999) Effect of antidepressant drug counselling and information leaflets on adherence to drug treatment in primary care, randomised controlled trial. BMJ, 319, 612–615.
Poirier, M. F. & Boyer, P. (1999) Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. British Journal of Psychiatry, 175, 12–16.
Posternak, M. A. & Zimmerman, M. (2001) Switching versus augmentation, a prospective, naturalistic comparison in depressed, treatment-resistant patients. Journal of Clinical Psychiatry, 62, 135–142.
Quitkin, F. M., Stewart, J. W., McGrath, P. J.
et al (1993) Loss of drug effects during continuation therapy. American Journal of Psychiatry, 150, 562–565.
Smith, D., Dempster, C., Glanville, J.
et al (2002) Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. British Journal of Psychiatry, 180, 396–404.
Stewart, J. W., Quitkin, F. M., McGrath, P. J.
et al (1998) Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Archives of General Psychiatry, 55, 334–343.
Thase, M. E., Entsuah, A. R. & Rudolph, R. L. (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry, 178, 234–241.
Tignol, J., Stoker, M. J. & Dunbar, G. C. (1992) Paroxetine in the treatment of melancholia and severe depression. International Clinical Psychopharmacology, 7, 91–94.
Zimmerman, M. & Posternak, M. A. (2002) Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?
American Journal of Psychiatry, 159, 469–473.